In adult patients with sickle cell disease two distinct subphenotypes have previously been defined: patients with the viscosity-vaso-occlusion subphenotype (VVO) suffer mainly from vaso-occlusive pain crises and have a relatively high hemoglobin concentration. Patients classified as the hemolysis-endothelial dysfunction subphenotype (HED) suffer from stroke and pulmonary hypertension and have an elevated concentration of lactate dehydrogenase. However, this classification is not possible in children due to low rates of complications. We used laboratory markers to classify children into the two subphenotypes, and measured vWF and vWF propeptide as markers of endothelial dysfunction. We included 106 children with sickle cell disease (mean age 8.7 years), 74 (70%) with HbSS/HbSβ°genotype and 32 (30%) with HbSC/HbSβ + genotype. vWF and vWF propeptide were significantly elevated in patients with sickle cell disease; this was more pronounced in patients with the HbSS/HbSβ°genotype. Patients with the HED subphenotype had higher levels of vWF propeptide, and a trend towards higher levels of vWF compared to those with the VVO subphenotype. We demonstrated that even young children in a stable clinical condition show signs of persistent endothelial dysfunction. A prospective study should demonstrate whether elevated levels of vWF and its propeptide are associated with an increased risk of complications specific for the HED subphenotype.
Introduction
Sickle cell disease (SCD) is a heterogeneous disorder with a highly variable clinical spectrum. To improve our understanding of the diversity in clinical presentation, Kato et al. postulated a classification of two clinical subphenotypes in adult patients [1] . According to this classification, patients with the viscosity-vaso-occlusion subphenotype (VVO) have a relatively high hemoglobin level and experience frequent vaso-occlusive pain crises, acute chest syndrome and osteonecrosis. At the other end of the spectrum are patients with the hemolysisendothelial dysfunction subphenotype (HED); these patients have high levels of lactate dehydrogenase (LDH) and a high reticulocyte count and their clinical picture is characterized by stroke, pulmonary hypertension, priapism and leg ulcers [2] . It would be useful to identify pediatric SCD patients with the HED or VVO subphenotype to be able to screen for these specific complications. However, it is difficult to distinguish the two subphenotypes in young patients because the rate of complications is still low.
The exact pathophysiology of the subphenotypes remains unclear. A reduced bioavailability of nitric oxide (NO) due to intravascular hemolysis has been suggested to play an important role in endothelial dysfunction and in particular in pulmonary hypertension. Whether a decreased level of NO is a true cause of endothelial dysfunction or a secondary phenomenon remains a subject of debate [3] [4] [5] .
Von Willebrand factor (vWF) is a sensitive marker of endothelial dysfunction. Several reports have demonstrated elevated levels of vWF in adult patients with SCD [6] [7] [8] [9] . The plasma concentration of vWF is higher in patients with a severe genotype (HbSS or HbSβ°) compared to patients with a moderate genotype (HbSC or HbSβ + ) [9] . There is very limited information on vWF plasma concentration in children with SCD. In a small study, 10 children with sickle cell disease and nocturnal hypoxemia were found to have elevated levels of vWF [10] but further studies on vWF in children with SCD are lacking.
vWF is released into the circulation by a constitutive pathway and a regulated pathway. After stimulation of the endothelium, the regulated Contents lists available at ScienceDirect
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j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / t h r o m r e s pathway is activated and vWF that is stored in Weibel-Palade bodies undergoes cleavage of its propeptide. Subsequently, both mature vWF and its propeptide are secreted into the bloodstream. vWF propeptide returns to baseline values within approximately 7 hours after acute activation of the endothelium, whereas the increase of mature vWF is longer due to a four-to fivefold longer half-life [11] . Thus, in chronic endothelial dysfunction, levels of vWF propeptide are not increased. This was illustrated in patients with diabetes who were found to have an elevated level of mature vWF but a normal concentration of vWF propeptide [12] . Both mature vWF and vWF propeptide may serve as indicators of future complications caused by endothelial dysfunction. This has been demonstrated in a prospective study of 102 children with insulindependent diabetes. A subgroup of patients developed elevated plasma concentrations of vWF and vWF propeptide. During a two year follow up, these children developed microalbuminuria, in contrast to the subgroup who did not have elevated plasma concentrations of vWF and vWF propeptide [13] . The results of this study suggest a relation between endothelial dysfunction and nephropathy.
vWF propeptide has never been studied in patients with SCD before. In the present study, we assessed plasma levels of vWF and its propeptide in a large group of young children with sickle cell disease in order to investigate endothelial dysfunction. Furthermore, we investigated whether vWF and vWF propeptide are influenced by genotype, haplotype or subphenotype.
Methods

Patients
All children between 2-18 years with SCD treated at the Emma Children's Hospital of the AMC were eligible to participate in the study. Collection of blood samples was carried out during regular visits to the outpatient clinic when patients were in a stable clinical condition (i.e. no vaso-occlusive crises, infections or blood transfusions 3 months prior to collection of blood samples). Patients using hydroxyurea and those on chronic blood transfusions were excluded.
Patients with HbSS or HbSβ°were considered to have a severe genotype and patients with HbSC or HbSβ + a mild genotype.
The medical ethics committee approved the study protocol and written informed consent was obtained from all participants.
Laboratory Parameters
vWF plasma concentration was measured by enzyme-linked immunosorbent assay (ELISA) (Dakopatts) [14] . vWF propeptide was assessed using CLB-pro, an antibody against vWF propeptide [11] . To assess coagulation activation, prothrombin fragment 1 and 2 (F1 + 2) was measured by ELISA using a mouse anti-human antibody [15] . Thrombin-antithrombin complex (TAT) was measured by ELISA using a rabbit anti-human antibody (Enzygnost) [16] .
Hematological parameters including hemoglobin (Hb), reticulocytes and coagulation factor FVIII were measured. In addition, LDH was assessed. Hemoglobin F percentage (HbF) was only measured in children N36 months to eliminate the effect of neonatal HbF.
Laboratory parameters were classified as abnormal when they were elevated 2 standard deviations (SD) above the mean of the normal population.
Haplotypes
Haplotype analysis of the β-globin gene cluster was performed by high-resolution melting curve analysis, as described previously [17, 18] , using the LightScanner instrument and software (LightScanner; Idaho Technologies Inc., USA). Only patients with a severe genotype (HbSS/HbSβ°) were included in this analysis. Central African Republic (CAR) haplotype is considered to be the most severely affected haplotype and Benin haplotype a more moderate haplotype. Therefore we compared patients with at least one allele of the CAR haplotype (homozygous or heterozygous) with patients homozygous for Benin haplotype.
Subphenotypes
In our pediatric study population the complication rate is low and therefore it was not possible to definitely classify patients into the two subphenotypes based on clinical events. Because a relatively high level of hemoglobin is a characteristic of the VVO subphenotype, we classified patients within the upper quartile of hemoglobin level as the VVO subphenotype. Hemolysis is a hallmark of the HED subphenotype; therefore we classified patients within the upper quartile of LDH as the HED subphenotype. Although in adult patients with SCD, reticulocyte count is the best parameter for hemolysis [3] , in children the reticulocyte count is highly dependent on several other factors, such as iron deficiency, bone marrow depression and infection. Therefore we used LDH as a more robust marker of hemolysis in children with SCD. To eliminate the effect of SCD genotype on the results, only patients with a severe genotype (HbSS/HbSβ°) were included in this analysis.
Definition of Clinical Events
Data were collected on lifetime complications. We scored admissions for vaso-occlusive pain episodes. Stroke is defined as a focal neurological deficit with evidence on neuroimaging of a cerebral infarct corresponding with the focal deficit. Silent cerebral infarcts (SCI) are areas of increased signal intensity on cerebral imaging (magnetic resonance imaging, MRI) without a history or physical findings of a focal neurological deficit. Cerebral vasculopathy is defined as an abnormal high blood flow velocity as assessed by transcranial Doppler ultrasonography or stenosis of an intracerebral artery of 50% or more as assessed by magnetic resonance angiography (MRA). Acute chest syndrome is defined as a new appearance of an infiltrate on chest radiograph in presence of pulmonary symptoms. Priapism is defined as a persistent and often painful penile erection. Avascular bone necrosis of hip or shoulder is defined as an abnormality seen on radiography due to bone infarction associated with chronic pain of the affected joint. Leg ulcers are defined as painful skin defects on (lower) legs.
Microalbuminuria
Microalbuminuria was defined as an elevated albumin/creatinine ratio (N2.5 mg albumin per mmol creatinine in men and N3.5 mg albumin per mmol creatinine in women). In some patients, only a urine dipstick test was performed. A positive result with urine dipstick was always confirmed by an elevated albumin/creatinine ratio.
Statistical Analyses
All presented laboratory values are mean values calculated over 1 to 3 hospital visits per patient. We used a one-sample t-test to evaluate differences between laboratory parameters of our study group and reference values. To test differences between 2 groups, a student's t-test was used in normally distributed data and a Mann-Whitney U test was used when data were not normally distributed. A Fisher's exact test was used to evaluate differences in complication rates between groups. To investigate the association between blood group and levels of vWF and vWF propeptide a one-way ANOVA was performed.
Results
We included 106 children with SCD, mean age 8.7 years (range 2.0 -17.5 years); the majority (70%) had a severe genotype (HbSS or HbSβ°).
Laboratory parameters are presented in Table 1 . The plasma concentrations of vWF and vWF propeptide were significantly higher in patients with SCD compared to the reference values (Table 1 , Fig. 1 ). Most patients (53%) had blood group O. vWF plasma concentration was lower in patients with blood group O compared to patients with blood group A, B or AB (p = 0.003 by ANOVA). The levels of vWF propeptide were not associated with blood group.
Genetic Variability
Patients with a severe genotype (HbSS or HbSβ°) had significantly higher concentrations of vWF and its propeptide and F1 + 2 and TAT compared to patients with a moderate genotype (HbSC or HbSβ + ) ( Table 1 , Fig. 1 ). In patients with a severe genotype, vWF and vWF propeptide were above the reference value in 32% and almost 24%, respectively.
The haplotype of the β globin gene cluster is a known modifier of clinical variability in SCD. Haplotype was available in 55 patients (74% of all patients with HbSS or HbSβ°). Most patients were homozygous for Benin haplotype (32 patients, 58%). Second most prevalent was CAR haplotype, with 7 homozygous patients (13%) and 5 heterozygous patients (9%). The remaining 11 patients (20%) had miscellaneous haplotypes (heterozygous for Benin or Senegal, Cameroon or undetermined haplotypes).
Compared to patients with a homozygous Benin haplotype, patients with at least one CAR haplotype had a lower leukocyte count, LDH and FVIII (Table 2) . We did not find a difference in markers of endothelial dysfunction or coagulation activation between these two haplotype groups.
Subphenotypes
The comparison of the two subphenotypes was restricted to patients with a severe genotype (HbSS or HbSβ°) ( Table 3) . Age was comparable between VVO and HED subphenotypes (8.5 ± 5.1 years vs 7.5 ± 4.0 years, p = 0.569) as was follow up time (13.3 ± 5.1 years vs 15.4 ± 5.8 years, p = 0.383) and blood group (53% blood group O vs 62%, p = 0.718). Hospitalization rate for vaso-occlusive pain episodes was very low and did not differ between the two subphenotypes. Cerebral vasculopathy was present in four patients with the HED subphenotype but in non of the patients with the VVO subphenotype.
Compared to the VVO subphenotype, patients in the HED group had more pronounced reticulocytosis (11.5% vs 6.8%, p = 0.022) and higher leukocyte count (13.7 × 10 9 /l vs 10.5 × 10 9 /l, p = 0.008). vWF and its propeptide were considerably higher in the HED group: 74 nmol/l vs 57nmol/l, p=0.104 and 7.6nmol/l vs 6.0nmol/l, p=0.008, respectively (Table 3) .
Microalbuminuria
In the total cohort, 17% of patients had micoralbuminuria (19% of patients with HbSS or HbSβ°and 13% of patients with HbSC or HbSβ + ). In patients with a severe genotype, there was a trend towards a higher vWF propeptide in patients who had microalbuminuria compared to patients who did not have microalbuminuria (8.5 nmol/l vs 7.3 nmol/l, p = 0.068). There was also trend towards a higher plasma concentration of vWF in (78 nmol/l vs 70 nmol/l, p = 0.130). Also in patients with a mild genotype, there was a trend towards a higher vWF propeptide in patients who had microalbuminuria compared to patients who did not have microalbuminuria (4.4 nmol/l vs 6.5 nmol/l, p = 0.062).
Discussion
Despite the young age and the stable clinical condition at the time of testing, we found an abnormal high plasma concentration of vWF and vWF propeptide in our patients. This was more pronounced in patients with a severe genotype and in patients in the HED subphenotype. This is the first large study to evaluate vWF and vWF propeptide in young children with sickle cell disease. vWF is directly involved in adhesion of sickle red blood cells to the endothelium and is a promising parameter of endothelial dysfunction to study in SCD [19] .
Even in the absence of clinical signs of vaso-occlusion or infection, we found an elevated concentration of vWF propeptide, although not of the same magnitude as previously described in the context of acute illness [12] . This indicates that some form of persistent endothelial activation is present in our patients. vWF propeptide is overwhelmingly elevated in the context of acute severe illness, e.g. malaria, sepsis and thrombotic thrombocytopenic purpura. Previous studies on small groups of adult patients with chronic vascular diseases (i.e. chronic kidney disease and ischemic heart disease) demonstrated an elevated level of vWF propeptide, reflecting continuous acute endothelial activation [20] [21] [22] [23] [24] . Our results show that a subgroup of children (24%) with a severe genotype has elevated levels of vWF propeptide (Fig. 1B) . Whether the elevated concentration of vWF propeptide in this group of patients could potentially predict specific complications in SCD and therefore indentify patients with a HED subphenotype should be studied further. We did find an association between vWF propeptide and micoralbuminuria, but due to the cross sectional design of our study, we could not investigate the time relation between endothelial dysfunction and micoralbuminuria. We analyzed the association of vWF and its propeptide with genotype, haplotype and subphenotype. The increase in vWF and vWF propeptide was more pronounced in patients with a severe genotype (HbSS or HbSβ°) compared to patients with a moderate genotype (HbSC or HbSβ + ). The elevated concentration of vWF in patients with a severe genotype was found previously in a study in adults by Mohan et al. [9] and a study by Nur et al. [8] , although this did not reach statistical significance in the latter study.
Our analysis of the association between haplotype and endothelial dysfunction was limited by lack of power, due to the lack of variation in haplotype within the study. There are no previous studies that have analyzed the association between haplotype and endothelial dysfunction. Prior studies on hematological differences between haplotypes are difficult to interpret because of conflicting results.
Patients with the HED subphenotype have a higher concentration vWF propeptide and a trend towards an elevated concentration of mature vWF, compared to patients with the VVO subphenotype. Chronic hemolysis, the hallmark ot the HED subphenotype, is associated with endothelial dysfunction although the exact mechanism remains unclear. Previous observations suggest that intravascular hemolysis leads to elevated plasma levels of cell free hemoglobin which produces reactive oxygen species. This results in scavenging of NO. In addition, hemolysis leads to the release of arginase into the plasma which metabolizes arginine and reduces the availability of substrate for NO production. The reduced bioavailability of NO may result in endothelial activation, enhanced expression of cell adhesion molecules and coagulation activation. However, as stated before, whether a decreased availability of NO is the true cause of endothelial dysfunction or a mere side effect remains unclear.
As vWF propeptide is considerably higher in the HED subphenotype, our results suggest that vWF propeptide is a potential predictor of subphenotype in young children. Our analysis was hampered by low complication rates in our young patient cohort (Table 3 ). The admission rate for vaso-occlusive pain episodes was very low, probably because most pain episodes are treated at home. However cerebral vasculopathy, a distinct feature of the HED subphenotype, was present in children with the HED subphenotype and not in patients with the VVO subphenotype (p = 0.035). A prospective study should determine whether elevated levels of vWF propeptide precede specific complications seen in patients with the HED subphenotype, for example stroke and pulmonary hypertension, and whether it can be used to target specific screening for these complications.
In summary, we demonstrated that even young children during stable clinical condition demonstrate signs of persistent endothelial dysfunction; this is more distinct in patients with a severe genotype and in patients classified as the HED subphenotype. A prospective study should demonstrate whether elevated levels of vWF and vWF propeptide predict an increased risk of complications specific for the HED subphenotype. 
